InsidersTradesSigma
Total declarations
Company
▲ Purchases (18 ops.)
▼ Sales (0 ops.)
Discover the complete record of transactions filed by Patel Snehal, Chairman & CEO. Director active across 1 companies, notably Greenwich LifeSciences, Inc.. In total, 18 disclosures have been published. Total volume traded: €1.1m. The latest transaction was disclosed on 16 June 2022 (Acquisition). Regulator: SEC (Form 4). The full history is free.
Declarations18 total
€54,0828,000 shares@ €6.76030.014% mcap4.9% of flow
Common Stock
SEC:0001493152-22-017036:0·
Ideal exit: 13 Mar 2023 (T+270)
€90,91412,000 shares@ €7.57620.024% mcap8.2% of flow
Common Stock
SEC:0001493152-22-016793:0·
Ideal exit: 11 Mar 2023 (T+270)
€94,13112,000 shares@ €7.84430.025% mcap8.5% of flow
Common Stock
SEC:0001493152-22-016504:0·
Ideal exit: 7 Mar 2023 (T+270)
€46,1904,500 shares@ €10.26440.012% mcap4.2% of flow
Common Stock
SEC:0001493152-22-016372:0·
Ideal exit: 6 Mar 2023 (T+270)
€47,9506,000 shares@ €7.99170.013% mcap4.3% of flow
Common Stock
SEC:0001493152-22-016131:0·
Ideal exit: 4 Mar 2023 (T+270)
€71,8429,250 shares@ €7.76670.019% mcap6.5% of flow
Common Stock
SEC:0001493152-22-015921:0·
Ideal exit: 28 Feb 2023 (T+270)
€46,5006,774 shares@ €6.86440.012% mcap4.2% of flow
Common Stock
SEC:0001493152-22-015769:0·
Ideal exit: 27 Feb 2023 (T+270)
€89,0996,000 shares@ €14.84980.024% mcap8.0% of flow
Common Stock
SEC:0001493152-22-010677:0·
Ideal exit: 16 Jan 2023 (T+270)
€93,0486,000 shares@ €15.50790.025% mcap8.4% of flow
Common Stock
SEC:0001493152-22-010575:0·
Ideal exit: 14 Jan 2023 (T+270)
€95,3965,500 shares@ €17.34480.025% mcap8.6% of flow
Common Stock
SEC:0001493152-22-004178:0·
Ideal exit: 8 Nov 2022 (T+270)
€85,6525,000 shares@ €17.13050.023% mcap45.0% of flow
Common Stock
SEC:0001213900-22-005787·
Ideal exit: 1 Nov 2022 (T+270)
€85,6525,000 shares@ €17.13050.023% mcap7.7% of flow
Common Stock
SEC:0001213900-22-005787:0·
Ideal exit: 1 Nov 2022 (T+270)
€17,4711,000 shares@ €17.47130.0046% mcap9.2% of flow
Common Stock
SEC:0001493152-22-001375·
Ideal exit: 10 Oct 2022 (T+270)
€17,4711,000 shares@ €17.47130.0046% mcap1.6% of flow
Common Stock
SEC:0001493152-22-001375:0·
Ideal exit: 10 Oct 2022 (T+270)
€42,9342,050 shares@ €20.94340.011% mcap22.6% of flow
Common Stock
SEC:0001493152-22-000212·
Ideal exit: 30 Sept 2022 (T+270)
€42,9342,050 shares@ €20.94340.011% mcap3.9% of flow
Common Stock
SEC:0001493152-22-000212:0·
Ideal exit: 30 Sept 2022 (T+270)
€44,2981,840 shares@ €24.07520.012% mcap23.3% of flow
Common Stock
SEC:0001493152-21-031655·
Ideal exit: 10 Sept 2022 (T+270)
€44,2981,840 shares@ €24.07520.012% mcap4.0% of flow
Common Stock
SEC:0001493152-21-031655:0·
Ideal exit: 10 Sept 2022 (T+270)
18 of 18 declarations
About Patel Snehal
Snehal Patel is an executive at Greenwich LifeSciences, Inc.
